Thalidomide for chronic sarcoidosis

Chest

Volumn 122, Issue 1, 2002, Pages 227-232

  Baughman, Robert P ^a   Judson, Marc A ^b   Teirstein, Alvin S ^c   Moller, David R ^d   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Corticosteroids; Lupus pernio; Sarcoidosis; Thalidomide; Tumor necrosis factor

Indexed keywords

THALIDOMIDE;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DYSPNEA; FEMALE; HUMAN; MALE; PARESTHESIA; PHOTOGRAPHY; PRIORITY JOURNAL; RASH; SARCOIDOSIS; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SKIN DEFECT; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO;

EID: 0036308591     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.122.1.227     Document Type: Article

References (30)

1. Thalidomide in the treatment of lepra reaction
2. Thalidomide responsive chronic pulmonary GVHD
3. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: Clinical tolerance and effect on activation markers and cytokines
4. Thalidomide as replacement for steroids in immunosuppression after lung transplantation
5. Antitumor activity of thalidomide in refractory multiple myeloma
6. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis
7. Thalidomide treatment reduces tumor necrosis factor α production and enhances weight gain in patients with pulmonary tuberculosis
8. Statement on sarcoidosis: Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999
9. Current concepts of the pathogenesis of sarcoidosis
10. 2 release, alveolitis, and disease severity in sarcoidosis
11. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis
12. Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages
13. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide
14. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report
15. Prognostic factors predicting the outcome of sarcoidosis: An analysis of 818 patients
16. Alternatives to corticosteroids in the treatment of sarcoidosis
17. Defining organ involvement in sarcoidosis: The ACCESS proposed instrument
18. Spirometric reference values from a sample of the general U.S. population
19. Reliability of a widely used test of peripheral cutaneous vibration sensitivity and a comparison of two testing protocols
20. Invasive nasal sarcoidosis treated with methotrexate
21. Nasal and sinus manifestations of sarcoidosis
22. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis
23. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical trials group
24. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
25. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis
26. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis
27. Inhibition of IL-12 production by thalidomide
28. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α
29. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome
30. The use of low dose methotrexate in refractory sarcoidosis